CN101437540B - 结合黑皮质素受体的拟抗体、组合物、方法和用途 - Google Patents

结合黑皮质素受体的拟抗体、组合物、方法和用途 Download PDF

Info

Publication number
CN101437540B
CN101437540B CN2005800447902A CN200580044790A CN101437540B CN 101437540 B CN101437540 B CN 101437540B CN 2005800447902 A CN2005800447902 A CN 2005800447902A CN 200580044790 A CN200580044790 A CN 200580044790A CN 101437540 B CN101437540 B CN 101437540B
Authority
CN
China
Prior art keywords
seq
polypeptide
mimetibody
msh
melanocortin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800447902A
Other languages
English (en)
Chinese (zh)
Other versions
CN101437540A (zh
Inventor
M·坎宁安
V·斯托亚诺维克-苏苏利克
K·奥奈尔
黄冲
J·罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of CN101437540A publication Critical patent/CN101437540A/zh
Application granted granted Critical
Publication of CN101437540B publication Critical patent/CN101437540B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2005800447902A 2004-10-25 2005-10-25 结合黑皮质素受体的拟抗体、组合物、方法和用途 Expired - Fee Related CN101437540B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62196004P 2004-10-25 2004-10-25
US60/621,960 2004-10-25
PCT/US2005/038431 WO2006047535A2 (en) 2004-10-25 2005-10-25 Melanocortin receptor binding mimetibodies, compositions, methods and uses

Publications (2)

Publication Number Publication Date
CN101437540A CN101437540A (zh) 2009-05-20
CN101437540B true CN101437540B (zh) 2012-12-19

Family

ID=36228385

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800447902A Expired - Fee Related CN101437540B (zh) 2004-10-25 2005-10-25 结合黑皮质素受体的拟抗体、组合物、方法和用途

Country Status (28)

Country Link
US (1) US20060105951A1 (enExample)
EP (1) EP1812046B1 (enExample)
JP (1) JP2008517605A (enExample)
KR (1) KR101255140B1 (enExample)
CN (1) CN101437540B (enExample)
AT (1) ATE501731T1 (enExample)
AU (1) AU2005299440B2 (enExample)
BR (1) BRPI0518411A2 (enExample)
CA (1) CA2585287A1 (enExample)
CY (1) CY1111486T1 (enExample)
DE (1) DE602005026970D1 (enExample)
DK (1) DK1812046T3 (enExample)
EA (1) EA200700944A1 (enExample)
EC (1) ECSP077416A (enExample)
ES (1) ES2363023T3 (enExample)
HR (1) HRP20110405T1 (enExample)
IL (1) IL182683A0 (enExample)
MA (1) MA28943B1 (enExample)
ME (1) ME01234B (enExample)
MX (1) MX2007004974A (enExample)
NO (1) NO20072499L (enExample)
PL (1) PL1812046T3 (enExample)
PT (1) PT1812046E (enExample)
RS (1) RS51789B (enExample)
SI (1) SI1812046T1 (enExample)
TN (1) TNSN07157A1 (enExample)
WO (1) WO2006047535A2 (enExample)
ZA (1) ZA200704260B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
US7790671B2 (en) * 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
AU2009257631B2 (en) 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
US8614185B2 (en) * 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CN105037502A (zh) 2009-06-08 2015-11-11 帕拉丁科技公司 黑皮质素受体特异性肽
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
KR20120102716A (ko) 2009-11-23 2012-09-18 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴-1 수용체 특이적 선형 펩티드
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
CN113272330B (zh) * 2019-03-02 2024-07-26 南通壹宸生物医药科技有限公司 一种双特异抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033658A1 (en) 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
AU2001275930B2 (en) * 2000-07-14 2007-05-10 Eisai Inc. Alpha-msh related compounds and methods of use
AU2003256336A1 (en) * 2002-06-28 2004-01-19 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
EP1545608A4 (en) * 2002-06-28 2006-09-13 Centocor Inc CH1-DELETED MAMMED MUICETIC BODIES, COMPOSITIONS, METHODS AND APPLICATIONS
EA011583B1 (ru) * 2004-03-31 2009-04-28 Сентокор, Инк. Миметические антитела glp-1 человека, композиции, способы и применения

Also Published As

Publication number Publication date
IL182683A0 (en) 2007-09-20
ZA200704260B (en) 2009-03-25
TNSN07157A1 (en) 2008-11-21
CY1111486T1 (el) 2015-08-05
KR101255140B1 (ko) 2013-04-22
WO2006047535A2 (en) 2006-05-04
AU2005299440B2 (en) 2011-12-15
MA28943B1 (fr) 2007-10-01
CN101437540A (zh) 2009-05-20
US20060105951A1 (en) 2006-05-18
MX2007004974A (es) 2007-10-17
WO2006047535A3 (en) 2008-09-04
SI1812046T1 (sl) 2011-06-30
DE602005026970D1 (de) 2011-04-28
ME01234B (me) 2013-06-20
ES2363023T3 (es) 2011-07-19
KR20070085416A (ko) 2007-08-27
BRPI0518411A2 (pt) 2008-11-18
EA200700944A1 (ru) 2008-04-28
ATE501731T1 (de) 2011-04-15
HRP20110405T1 (hr) 2011-06-30
DK1812046T3 (da) 2011-06-06
AU2005299440A1 (en) 2006-05-04
CA2585287A1 (en) 2006-05-04
EP1812046B1 (en) 2011-03-16
JP2008517605A (ja) 2008-05-29
HK1106445A1 (en) 2008-03-14
ECSP077416A (es) 2007-05-30
RS51789B (sr) 2011-12-31
EP1812046A2 (en) 2007-08-01
PT1812046E (pt) 2011-06-28
EP1812046A4 (en) 2009-11-11
PL1812046T3 (pl) 2011-08-31
NO20072499L (no) 2007-07-16

Similar Documents

Publication Publication Date Title
EP2214690B1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
US8722615B2 (en) Compositions and methods for increasing serum half-life
CN114846025B (zh) 超长效胰岛素-Fc融合蛋白及其使用方法
CN101437540B (zh) 结合黑皮质素受体的拟抗体、组合物、方法和用途
JP2008537874A (ja) ｓＲＡＧＥミメティボディ、組成物、方法および使用
JP5751641B2 (ja) メラノコルチン受容体結合コンジュゲート
CN113271972B (zh) 用于替代IVIG的多聚体杂交Fc蛋白
TW202317607A (zh) 融合蛋白及其應用
EP1792626B1 (en) Treatment of obesity with alpha-MSH mimetibodies
WO2023125881A1 (zh) Glp-1和gdf15的融合蛋白及其用途
WO2006138610A2 (en) Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof
HK1106445B (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
KR20220157910A (ko) Gdf15 변이체 및 glp-1 수용체 작용제를 포함하는 병용 투여용 조성물
CA2704446A1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2023025129A1 (zh) Gdf15融合蛋白及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121219

Termination date: 20171025

CF01 Termination of patent right due to non-payment of annual fee